Is Cycling Good For Weight Loss? Honest Evidence Review

The honest answer: yes, modestly. Cycling burns ~280 kcal/h at leisurely pace and ~560-980 kcal/h at vigorous-to- racing pace for a 70 kg adult per the ACSM Compendium of Physical Activities^[1]. RCTs of structured cycling without diet change produce 1-3% body weight loss over 6-12 months — clinically meaningful but modest. Cycling's real edge over running is joint-friendliness and sustainability for high-BMI patients. Cycling at 19-22 km/h moderate effort is ~8 METs, vigorous 22-26 km/h is ~10 METs, and racing >26 km/h is ~12 METs per the canonical Ainsworth Compendium^[1]. At these intensities a 70 kg adult burns ~560, ~700, and ~840 kcal/h respectively. The Slentz STRRIDE trial^[2] (Archives of Internal Medicine, 2004) randomized 120 overweight adults to 8 months of supervised aerobic training (treadmill, cycle ergometer, or elliptical) at three doses plus a sedentary control. The high-amount/vigorous group lost ~3.5% body weight and ~3.0 kg of fat mass; the low-amount/moderate group held weight steady while the sedentary control group gained ~1.1 kg. The Andersen 2000 Copenhagen cohort^[7] followed ~30,640 adults and found that cycling to work was associated with ~28% lower all-cause mortality after adjustment for other leisure-time physical activity. The Lusk 2010 Nurses' Health Study II cohort^[8] (n=18,414 premenopausal women, 16-year follow-up) reported women adding ≥30 min/day of bicycling between 1989 and 2005 gained ~1.6 kg less than women who reduced cycling or didn't cycle. The honest framing: any structured aerobic exercise produces similar weight loss per equivalent calorie deficit; cycling's edge is adherence — joint-friendly enough to sustain for high-BMI patients, can be done indoors while reading or working, and integrates into commuting in a way running rarely does.

The honest summary

• Energy cost of cycling by intensity (70 kg adult, ACSM Compendium FDC METs^[1]): leisurely (≤16 km/h) ~4 METs ~280 kcal/h; light (16-19 km/h) ~6 METs ~420 kcal/h; moderate (19-22 km/h) ~8 METs ~560 kcal/h; vigorous (22-26 km/h) ~10 METs ~700 kcal/h; racing (>26 km/h) ~12 METs ~840 kcal/h. Per-kilometer rule: ~0.3-0.4 kcal/kg/km for outdoor cycling — roughly one-third the per-distance cost of running (~1 kcal/kg/km).
• STRRIDE 2004 (Slentz, PMID 14718319): 120 overweight adults, 8 months of supervised aerobic training at three doses (low-amount/moderate, low-amount/vigorous, high-amount/vigorous) using treadmill + cycle ergometer + elliptical, plus sedentary control. The high-amount/vigorous arm lost ~3.5% body weight and ~3.0 kg of fat mass with no dietary intervention; the control group gained ~1.1 kg over the same 8 months. Cleanest direct evidence that structured cycling-inclusive aerobic training produces modest but meaningful weight loss without diet change.
• Andersen 2000 Copenhagen cohort (PMID 10847255): ~30,640 adults, 14.5-year follow-up. Cycling to work associated with HR 0.72 for all-cause mortality (~28% reduction) after adjustment for leisure-time physical activity. The first major cohort to identify commuter cycling as an independent mortality-protective behavior.
• Lusk 2010 Nurses' Health Study II (PMID 20585071): n=18,414 premenopausal women, 16-yr follow-up. Women adding ≥30 min/day of bicycling between 1989 and 2005 gained ~1.6 kg less than women who reduced cycling. Slow walking was not associated with reduced weight gain; brisk walking and any bicycling were. The signal favored cycling specifically for weight-gain prevention in midlife women.
• Celis-Morales 2017 UK Biobank (PMID 28424154): n=263,450, 5-yr median follow-up. Cycle commuting associated with HR 0.59 (95% CI 0.42-0.83) for all-cause mortality, 0.54 for cardiovascular mortality, and 0.60 for cancer mortality vs non-active commuting. The strongest single signal in the active-commuting literature.
• Joint-impact advantage vs running: peak knee forces in steady-state cycling are ~1-1.5× body weight; running peaks at ~3-5× body weight at ground-strike. For BMI ≥30 patients, BMI ≥35 patients, patients with prior knee/hip surgery, and patients with early osteoarthritis, cycling is the highest-volume aerobic modality the joints can tolerate. Real edge over running, not marketing.
• Caloric deficit is still required. The ACSM 2009 threshold^[5] for clinically significant weight loss is ≥250 min/wk of moderate-intensity activity (~150 min/wk vigorous, or 3-4 cycling sessions of 45-50 min). At 19-22 km/h moderate cycling for 200 min/wk, a 70 kg adult burns ~1,900 kcal/wk — ~0.25 kg/wk theoretical fat loss before compensatory eating offsets 30-50%. Diet remains the load-bearing lever; cycling is the amplifier and the cardiometabolic-mortality contributor.
• Magnitude vs GLP-1s: cycling alone produces ~1-3% body weight loss over 6-12 months without diet change. STEP-1 semaglutide^[10] produced -14.9% at 68 weeks; SURMOUNT-1 tirzepatide^[11] -20.9% at 72 weeks. Cycling is not in the magnitude class of obesity pharmacotherapy. It is the highest-leverage adherent aerobic modality for the high-BMI patient on or off a GLP-1.

Energy cost of cycling by intensity

Cycling caloric burn is the load-bearing number for most weight-loss questions. The mechanistic anchor is the Ainsworth Compendium of Physical Activities^[1] (2011 second update, the canonical reference for epidemiology and exercise prescription), which assigns cycling MET values by intensity tier. One MET is approximately 1 kcal/kg/h, so per-hour expenditure scales linearly with body weight.

Two practical implications fall out of the table. First, cycling at conversational pace burns less per hour than running at the same RPE — leisurely cycling (~280 kcal/h for a 70 kg adult) is closer to brisk walking (~280 kcal/h) than to slow jogging (~630 kcal/h). The per-hour caloric edge of cycling shows up at moderate-to- vigorous intensities (~560-840 kcal/h), which require actually pushing the pace, not coasting on a path. Second, stationary cycling at power-meter-defined output burns very predictable calories — 100 W ≈ 6.8 METs, 150 W ≈ 8.8 METs, 200 W ≈ 11 METs, scaling linearly with body weight. This makes indoor cycling (Peloton, gym stationary, smart trainer with power meter) the most precisely-prescribable aerobic modality for a calorie-target program.

Magnitude comparison vs GLP-1s and other modalities

Cycling is not in the magnitude class of FDA-approved obesity pharmacotherapy. Its evidence-based role is as a deficit-amplifier paired with caloric restriction and a sustainability anchor for adherent activity over years. The Foster-Schubert 12-month data^[4] remain the cleanest single-trial demonstration that diet alone produces ~3.5× the weight loss of exercise alone, but diet + exercise produces ~27% more than diet alone. The pattern is unambiguous: dietary change is the load-bearing intervention; cycling amplifies it and independently improves cardiorespiratory fitness, visceral-fat-driven metabolic risk, and (per Andersen^[7] and Celis-Morales^[9]) all-cause mortality.

Cycling vs running for high-BMI patients

This is where cycling earns its place over running for a large fraction of the weight-loss population. The biomechanics are well-characterized and the clinical implications matter.

Joint loading. Peak knee compression forces during steady-state running are approximately 3-5 times body weight at ground-strike; during steady-state cycling they are approximately 1.0-1.5 times body weight, distributed continuously rather than in repeated high-magnitude impact events. For a 100 kg patient, this is the difference between 300-500 kg of peak impact force per stride (1,500-2,500 strides per 30 minutes of running) and a smoothly modulated 100-150 kg compression through the pedal stroke. The cumulative joint stress per equivalent caloric expenditure favors cycling by roughly an order of magnitude.

Clinical patient groups where cycling wins.

• BMI ≥30 starting weight: running induces knee and hip pain in a substantial fraction of new runners; cycling at the same caloric expenditure is tolerated by nearly all comers. Adherence over months — which is what produces weight loss — favors cycling for this group.
• BMI ≥35 or ≥40: running is rarely sustainable past 10-15 minutes for most patients in this range due to knee, hip, ankle, and lumbar discomfort plus cardiorespiratory limits. Cycling — particularly recumbent stationary cycling — can extend to 30-60 min sessions at meaningful intensity.
• Prior knee or hip surgery / replacement: most orthopedic post-operative protocols clear cycling earlier than running, often by months. Cycling is the first aerobic modality cleared in TKA, THA, and ACL rehab.
• Early osteoarthritis: meta-analytic evidence favors cycling as the lower-symptom-burden aerobic option for OA patients. Running can be tolerated (and is not contraindicated for early OA), but cycling produces fewer pain days per equivalent training stimulus.
• Pregnancy and postpartum recovery: stationary cycling is routinely permitted into late pregnancy after individualized clearance; running often isn't past the second trimester.
• Lower-back pain history: recumbent stationary cycling avoids the lumbar-loading pattern of upright cycling and the spinal-impact pattern of running.

For high-BMI patients planning a GLP-1 weight-loss program, cycling is the highest-leverage aerobic modality through the peak weight-loss phase (typically months 4-12) when joint forces drop progressively but cardiorespiratory volume can ramp meaningfully. Running can enter the program later, once BMI has dropped enough that the joint-impact case shifts. Our full pairing protocol is in the exercise-pairing hub for GLP-1 lean-mass preservation.

Stationary bike vs outdoor cycling

For weight loss the choice is mostly about adherence and precision, not physiology. Same calories burn at same power output regardless of whether you're on a road, gravel, or smart trainer.

Stationary cycling — what it's good for. Precisely-prescribable caloric output (the power meter removes the "am I really at moderate intensity" guesswork). Weather-independent — eliminates the November- through-March compliance cliff that hits outdoor cyclists in most US latitudes. Can be done while reading, watching TV, listening to long-form audio, or doing video calls at zone-2 intensity. Recumbent variants accommodate lower-back and balance concerns. Indoor-cycling classes (Peloton, SoulCycle-style, gym group rides) provide adherence-enhancing social structure that outdoor solo riding doesn't.

Outdoor cycling — what it's good for. Commute integration — the strongest mortality signal in the cycling literature comes from commuter cycling (Andersen 2000^[7], Celis-Morales 2017^[9]), not recreational riding. Built-in NEAT increase from weight-bearing transitions (mounting, dismounting, navigating intersections). Higher caloric burn from wind resistance, terrain variation, and the unavoidable surging of group rides. Lower per-hour boredom for most riders — adherence advantage that compounds over years.

The commute-cycling-specific evidence. Andersen 2000^[7] followed ~30,640 Copenhagen adults for 14.5 years and found cycling to work — after adjustment for leisure-time physical activity, smoking, BMI, cholesterol, and other cardiovascular risk factors — independently associated with ~28% lower all-cause mortality. The 2017 UK Biobank analysis (Celis-Morales^[9], n=263,450, 5-year follow-up) reported even stronger signals: HR 0.59 for all-cause mortality, 0.54 for cardiovascular mortality, and 0.60 for cancer mortality vs non-active commuting. The signal survived sensitivity analysis and was robust across age, sex, BMI, and pre-existing disease subgroups. The active-commuting literature is one of the cleanest cohort-level demonstrations that integrating aerobic activity into the daily structure of life produces bigger downstream benefits than the same total minutes scheduled as recreational exercise.

Pragmatic guidance. If you have a cycle-able commute and tolerate the gear and route logistics, commute cycling captures the strongest mortality signal in the literature and is the highest-yield use of cycling time. If you don't — stationary cycling at home or in a gym is the next-best option, with the advantage that intensity is precisely controllable and adherence is weather-proof. The wrong move is treating outdoor recreational cycling as the default when commute integration is feasible.

RCT evidence: what cycling and aerobic training actually do

STRRIDE 2004 (Slentz, PMID 14718319) — the cleanest dose- response trial

Slentz, Duscha, Johnson, and the Duke STRRIDE investigators (Archives of Internal Medicine, 2004) randomized ~120 sedentary, overweight, mildly-dyslipidemic men and women to 8 months of supervised aerobic training in one of three doses, plus an inactive control. Training modalities were treadmill walking/jogging, cycle ergometer, and elliptical — subjects self-selected per session. Doses:

• Low-amount / moderate-intensity: ~12 miles/ week at 40-55% peak VO2.
• Low-amount / vigorous-intensity: ~12 miles/ week at 65-80% peak VO2.
• High-amount / vigorous-intensity: ~20 miles/ week at 65-80% peak VO2.
• Control: sedentary, no training.

Critically, no dietary intervention was provided — subjects were instructed to maintain habitual diet, with quarterly check-ins to confirm. Results at 8 months:

• High-amount/vigorous group: ~3.5% body weight reduction, ~3.0 kg fat-mass reduction, no significant change in lean mass.
• Low-amount/vigorous group: body weight held steady (no significant gain or loss) — exercise volume sufficient to prevent the weight gain seen in controls but not produce frank weight loss.
• Low-amount/moderate group: small but significant fat-mass reduction; body weight stable.
• Control group: body weight increased ~1.1 kg over 8 months — the natural drift in this sedentary, mildly-dyslipidemic population.

STRRIDE is the cleanest dose-response demonstration in the cycling-inclusive aerobic-exercise literature. Two takeaways survive translation to clinical practice: (1) you need enough volume. Below ~150 min/wk of vigorous cycling-equivalent aerobic training, you can hold weight steady but not lose meaningful weight without diet change. (2) The ceiling without diet change is modest. Even at ~20 miles/week of vigorous training — a substantial time commitment — the 8-month yield is ~3.5% body weight, roughly 3 kg for a 90 kg adult.

Willis 2012 STRRIDE AT/RT (PMID 23019316) — aerobic vs resistance head-to-head

The follow-up STRRIDE AT/RT trial^[3] (Journal of Applied Physiology, 2012) randomized 234 overweight or obese adults to 8 months of aerobic training, resistance training, or combined. The aerobic arm used the same cycle-ergometer + treadmill + elliptical menu as the original STRRIDE. Results:

• Aerobic group: lost ~1.8 kg body mass — statistically significant but modest.
• Combined aerobic + resistance: lost ~2.4 kg — numerically the largest reduction.
• Resistance-only group: did NOT produce significant body-mass reduction but increased lean mass — the canonical demonstration that resistance training is a body-composition tool, not a scale-weight tool.

For the cycling-specific case, Willis 2012 confirms that aerobic training (cycling-inclusive) is the dominant scale-weight lever in non-pharmacologic exercise programs, and that adding resistance training produces additive lean- mass benefits without compromising fat loss. For GLP-1 patients, the creatine + resistance training evidence layers on top of this aerobic base.

Foster-Schubert 2012 (PMID 21494229) — diet vs exercise hierarchy

Foster-Schubert and colleagues^[4] (Obesity (Silver Spring), 2012) randomized 439 overweight-to-obese postmenopausal women to four arms over 12 months: diet alone (10% weight-loss target via calorie restriction), exercise alone (45 min × 5 days/wk moderate-to-vigorous aerobic — primarily walking and cycling), diet + exercise, or control. Results at 12 months:

• Diet-alone arm: ~8.5% body weight loss.
• Exercise-alone arm: ~2.4% body weight loss — statistically significant but ~3.5× smaller than the diet effect.
• Diet + exercise arm: ~10.8% body weight loss — ~27% more than diet alone.
• Control: ~0.8% body weight loss (regression to the mean + assessment-driven behavior change).

Foster-Schubert remains the load-bearing single trial for the diet-vs-exercise hierarchy. The pattern generalizes across the broader literature: at typical sustainable weekly volumes, exercise alone produces ~2-3% body weight over 12 months; diet alone produces ~7-9%; combined produces ~10-12%. Cycling-inclusive aerobic exercise is the amplifier, not the primary lever, when scale weight is the outcome measure. When cardiorespiratory fitness, visceral-fat reduction, and all-cause mortality are the outcomes (per Andersen^[7] and Celis-Morales^[9]), cycling shifts to the primary lever.

Cohort evidence: cycling and long-term outcomes

Andersen 2000 Copenhagen cohort (PMID 10847255) — the canonical mortality signal

Andersen and colleagues^[7] (Archives of Internal Medicine, 2000) analyzed the Copenhagen Center for Prospective Population Studies, a ~30,640-person cohort followed for a mean of 14.5 years. The analytic question: does cycling to work, independent of leisure-time physical activity, predict mortality? The answer was unambiguous — after adjustment for age, sex, BMI, blood pressure, blood lipids, smoking, and leisure-time physical activity, cycling to work was associated with approximately 28% lower all-cause mortality (relative risk 0.72 in the multiply- adjusted model). The effect held across men and women and across leisure-time-active and leisure-time-sedentary subgroups. Andersen 2000 is the foundational paper for the active-commuting-and-mortality literature.

Lusk 2010 Nurses' Health Study II (PMID 20585071) — cycling and midlife weight gain

Lusk, Mekary, Feskanich, and Willett^[8] (Archives of Internal Medicine, 2010) examined bicycling, walking, and weight change among 18,414 premenopausal women in the Nurses' Health Study II over 16 years (1989- 2005). Key findings:

• Women who reported increasing bicycling by ≥30 min/day between 1989 and 2005 gained ~1.6 kg less than women who decreased or did no cycling.
• The bicycling weight-gain-prevention signal was not seen with slow walking — slow walking was unassociated with reduced weight gain in this cohort.
• Brisk walking and bicycling both showed protective signals for weight maintenance; bicycling specifically tracked with larger effect sizes per minute of activity.
• The protective signal was independent of total physical activity, suggesting cycling adds intensity per minute that slow walking doesn't.

Lusk 2010 is the strongest single cohort-level signal for cycling specifically (rather than aerobic activity generally) in midlife weight-gain prevention.

Celis-Morales 2017 UK Biobank (PMID 28424154) — the modern large-cohort confirmation

Celis-Morales and colleagues^[9] (BMJ, 2017) published the largest active-commuting cohort analysis to date: 263,450 UK Biobank participants followed for a median of 5 years. The headline numbers:

• Cycle commuting vs non-active commuting: HR 0.59 (95% CI 0.42-0.83) for all-cause mortality.
• Cardiovascular mortality: HR 0.54 (95% CI 0.33-0.88).
• Cancer mortality: HR 0.60 (95% CI 0.40-0.90).
• Mixed mode (cycle + other active): intermediate HRs.
• Walking commuting: smaller signal — HR 0.73 for cardiovascular disease incidence, no significant all-cause mortality signal.

The Celis-Morales analysis adjusted for sociodemographic, smoking, alcohol, diet, sedentary time, recreational physical activity, and BMI. The cycle-commuting effect survived. The UK Biobank data are sometimes criticized for healthy-volunteer bias — but the within-cohort comparison (cycle commuters vs non-active commuters in the same cohort) is robust to that critique. Combined with the Copenhagen and US-cohort signals, the cycle-commuting mortality protection is one of the most replicated cohort findings in the lifestyle-epidemiology literature.

Cycling + GLP-1 therapy

For patients already on semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), liraglutide (Saxenda), or orforglipron (Foundayo), cycling is arguably the highest-leverage aerobic modality available. The case rests on three points.

(1) Joint-friendliness during rapid weight loss. GLP-1 patients are commonly losing 0.5-1.5% body weight per week through months 4-12. During this window the joint forces across the knee and hip are progressively decreasing, but not yet at the lower-impact set point. Cycling permits meaningful aerobic volume (~150-250 min/wk) at peak knee forces of ~1-1.5× body weight, vs running at ~3-5× body weight at ground-strike. Adherence during this window is the binding constraint — cycling enables it.

(2) Lean-mass-preservation context. The SURMOUNT-1 DXA substudy^[11] documented that 25-39% of total weight lost on tirzepatide is lean tissue. Cycling produces cardiorespiratory fitness, glycemic improvement, visceral-fat reduction, and modest lower- extremity muscle-protein-synthesis stimulus — but does NOT produce the hypertrophy or strength-preservation signal of progressive resistance training. The honest pairing on a GLP-1 is cycling for aerobic volume + resistance training for lean-mass preservation + 1.2-1.6 g/kg/day protein. Cycling is the aerobic anchor; resistance training is the lean-mass lever. They are complementary, not substitutable. See our GLP-1 + creatine evidence review for the supplement layer, our exercise pairing hub for the full protocol, and our GLP-1 protein-first eating guide for the dietary layer.

(3) Tolerance during titration. Cycling sessions can be modulated more finely than running during the nausea-dominant phase of GLP-1 titration. Zone-2 stationary cycling at 30-50% peak power is well-tolerated on days when even moderate running is GI-uncomfortable. Patients can preserve aerobic adherence through the titration window with cycling that they couldn't with running. The full GLP-1 side-effect context is in our GLP-1 side-effect Q&A.

When cycling backfires for weight loss

Cycling earns its weight-loss place when used deliberately; the failure modes are predictable and documented.

(1) The post-ride snack trap — over-compensation. A 60-minute moderate ride burns ~560 kcal for a 70 kg adult. A post-ride smoothie + protein bar + sports drink can easily run 800-1,200 kcal. The cyclist-specific norm of "earned" calories — the cultural pattern of post- ride refueling adapted from endurance-athlete behavior — is the single most common reason recreational cyclists fail to lose weight despite logged hours. The compensation can run 100-150% of caloric expenditure, net-neutral or net-positive on the day's calorie balance. The honest rule for the weight-loss case: most rides <90 minutes don't require carbohydrate refueling beyond water and electrolytes.

(2) Coffee-shop social rides. The structural norm of group road cycling in the US — easy pace to a coffee stop, easy pace home — typically delivers 1-2 hours of zone-1 activity (~250 kcal/h for the cycling, ~400 kcal for the coffee-and-pastry stop). Net caloric effect is small or positive. This is a fine social pattern; it is not a weight-loss program. The cycling literature signals — STRRIDE high-amount/vigorous arm, Lusk NHS-II added-bicycling cohort — are at moderate-to-vigorous intensities, not social coffee-shop ride pace.

(3) Saddle-time injuries. Padded shorts and proper bike fit aren't optional past ~2 hours/week. Saddle sores, perineal numbness, and pudendal-nerve irritation are the most common adherence-killing complaints in new cyclists. A bike fit (~$100-200 one-time) and quality chamois shorts are the cheapest interventions to keep a new cyclist riding past the 3-month new-habit failure point.

(4) Overuse — IT band, knee tendinopathy, lower back. Cycling is lower-impact than running but not zero-impact. Rapid volume ramps (going from 0 to 150 min/wk in a month) commonly produce IT band syndrome, anterior knee pain, and lower-back tightness. The conservative progression is ~10%/week volume increase — same rule as running.

(5) Treating cycling as a license to skip resistance training. The Willis 2012 STRRIDE AT/RT data^[3] are unambiguous: aerobic-only training does not increase lean mass, and on a GLP-1 the absence of resistance training accelerates lean-mass loss. Cycling cannot substitute for resistance training in the body- composition case.

(6) E-bikes and motorized assist. Pedal- assist e-bikes increase ride frequency and commute feasibility, both of which are net positives. They also reduce per-minute energy expenditure ~25-40% depending on assist level. For caloric-deficit purposes, log e-bike time at lower MET assumptions (commuting on a Class 1 pedal- assist e-bike is closer to leisurely cycling, ~4-5 METs). The mortality-and-adherence benefits of cycling commuting likely transfer; the per-hour caloric burn doesn't.

Threshold guidance: how much cycling for clinically significant weight loss

Two authoritative guidelines define the exercise volume required for clinically significant weight loss.

ACSM 2009 position stand (Donnelly, PMID 19127177)^[5]: ≥250 min/wk of moderate-intensity activity is required for clinically significant weight loss; 150-250 min/wk prevents weight gain but produces only minimal direct weight loss; ≥250 min/wk + caloric restriction is the recommended combination for weight-loss maintenance. At vigorous intensity, minutes count double — so ~125 min/wk of vigorous cycling (22-26 km/h, ~10 METs) crosses the threshold.

HHS 2018 Physical Activity Guidelines (Piercy, PMID 30418471)^[6]: ≥150 min/wk moderate-intensity OR ≥75 min/wk vigorous-intensity aerobic activity, plus muscle-strengthening activities ≥2 days/wk. Additional health benefits accrue beyond the upper bound of the recommended range.

Practical cycling prescriptions for weight loss:

• Beginner / sedentary baseline: 3 sessions/ wk × 30 min at light-to-moderate intensity (16-19 km/h, ~420 kcal/h for 70 kg adult) = ~90 min/wk, ~630 kcal/wk burn. Hits HHS minimum at vigorous-equivalent. Hold for 4-6 weeks, then progress.
• Established weight-loss program (with caloric restriction): 4 sessions/wk × 45 min at moderate (19-22 km/h, ~560 kcal/h) = ~180 min/wk, ~1,680 kcal/wk burn. Exceeds HHS minimum, approaches ACSM weight-loss threshold at vigorous-equivalent.
• Aggressive aerobic prescription (high-amount STRRIDE arm): 5 sessions/wk × 50 min at vigorous (22-26 km/h, ~700 kcal/h) = ~250 min/wk, ~2,900 kcal/wk burn. STRRIDE-equivalent dose; ~3.5% body weight reduction at 8 months in the trial without diet change.
• Commute-cycling layer: 5 days × ~20 min each way × light-to-moderate intensity = ~200 min/wk of built-in cycling without scheduling separate workouts. Captures the strongest mortality signal in the literature (Andersen 2000, Celis-Morales 2017).
• Always pair with resistance training ≥2 days/wk for body-composition and lean-mass-preservation outcomes, per Willis 2012 STRRIDE AT/RT.

Bottom line

• Cycling burns approximately 280 kcal/h at leisurely pace, 560 kcal/h at moderate (19-22 km/h), 700 kcal/h at vigorous (22-26 km/h), and 840 kcal/h at racing pace (>26 km/h) for a 70 kg adult per the ACSM Compendium^[1]. Stationary cycling at 100 W is ~6.8 METs (~480 kcal/h for 70 kg); 150 W is ~8.8 METs (~620 kcal/h); 200 W is ~11 METs (~770 kcal/h).
• RCT evidence: STRRIDE high-amount/vigorous aerobic arm^[2] lost ~3.5% body weight at 8 months without diet change; Willis STRRIDE AT/RT aerobic arm^[3] lost ~1.8 kg over 8 months; Foster-Schubert^[4] exercise-alone postmenopausal arm lost ~2.4% at 12 months. Aerobic exercise alone produces 1-3% body weight loss without dietary change — clinically meaningful but modest.
• Cohort evidence: Andersen 2000 Copenhagen^[7] cycle-commuting ~28% lower all-cause mortality (HR 0.72); Celis-Morales 2017 UK Biobank^[9] cycle-commuting HR 0.59 for all-cause mortality and 0.54 for cardiovascular mortality; Lusk 2010 NHS-II^[8] women adding ≥30 min/day bicycling gained ~1.6 kg less over 16 years.
• Cycling's real edge over running is joint-friendliness and adherence — peak knee forces ~1-1.5× body weight (cycling) vs ~3-5× body weight (running). For BMI ≥30 patients, prior knee or hip surgery, early osteoarthritis, and high-BMI patients in the early phase of a GLP-1 program, cycling is the highest-volume tolerated aerobic modality.
• Caloric deficit remains the load-bearing lever. Cycling alone produces ~1-3% weight loss; diet alone produces ~7-9%; combined produces ~10-12% — per Foster-Schubert 2012^[4]. Cycling is the deficit-amplifier and the independent contributor to cardiorespiratory fitness, visceral-fat reduction, and all-cause mortality.
• For GLP-1 patients: cycling + resistance training ≥2 days/wk + 1.2-1.6 g/kg/day protein is the evidence-aligned pairing. Cycling is the aerobic anchor through the joint- impact-sensitive window of rapid weight loss; resistance training is the lean-mass lever; protein is the substrate.
• Magnitude check: STEP-1 semaglutide^[10] -14.9% at 68 weeks; SURMOUNT-1 tirzepatide^[11] -20.9% at 72 weeks. Cycling alone is not in the pharmacotherapy magnitude tier. It is the highest-leverage sustainable aerobic modality for the high-BMI patient population.
• The verdict: yes, modestly. Cycling earns a place in the weight-loss eating-and-moving plan for nearly every patient — strongest case for high-BMI patients, commute-cyclable city-dwellers, and GLP-1 patients through months 4-12 of titration. The dominant failure modes are post-ride snack over-compensation, social coffee-shop-pace rides treated as workouts, and rapid volume ramps causing knee/IT-band overuse.

Related research

• Is running good for weight loss? Honest evidence review — the closest exercise sibling. Running burns ~2× the per-kilometer calories of cycling but ~3-5× the peak joint forces. Side-by-side magnitude and tolerability comparison.
• Exercise pairing for GLP-1 lean-mass preservation — the full protocol where cycling sits as the aerobic anchor alongside progressive resistance training and protein targeting.
• GLP-1 + creatine for lean-mass preservation — the supplement layer that pairs with cycling + resistance training in the lean-mass-preservation case.
• GLP-1 side-effect Q&A — the side-effect context (nausea-dominant titration phase, GI tolerance) where cycling tolerates better than running.
• What to eat on a GLP-1: the protein-first guide — the dietary layer where the caloric-deficit load-bearing lever lives.
• Semaglutide and muscle-mass loss — the SURMOUNT-1 DXA evidence (25-39% lean-mass fraction of total weight loss) that makes the resistance-training case alongside cycling.
• Semaglutide (Wegovy / Ozempic) — STEP-1 magnitude reference (-14.9% body weight at 68 weeks).
• Tirzepatide (Zepbound / Mounjaro) — SURMOUNT-1 magnitude reference (-20.9% body weight at 72 weeks).

Important disclaimer. This article is educational and does not constitute medical advice. Patients with significant cardiovascular disease, uncontrolled hypertension, recent cardiac events, severe osteoarthritis, recent orthopedic surgery, or pregnancy should obtain individualized clearance from a physician before starting a new cycling program. Patients on semaglutide, tirzepatide, or other GLP-1 receptor agonists in the nausea-dominant titration phase should test individual tolerance with shorter lower-intensity sessions before scaling volume. Patients with type 2 diabetes on insulin or sulfonylureas should monitor for exercise-associated hypoglycemia. Helmet use is non-optional for any road or commute cycling. PMIDs were independently verified against the PubMed E-utilities API on 2026-05-19.

Last verified: 2026-05-19. Next review: every 12 months, or sooner if major new evidence on cycling, active commuting, body weight, or cardiometabolic outcomes is published.